Corticotropin

Generic Name: Corticotropin

Brand Names: Acthar, Cortrophin

Drug Type: Biotech

CAS Number: 12427-33-7

Unique Ingredient Identifier: K0U68Q2TXA

Background: Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication: For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions: Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis

Clinical Trials

ACTH Treatment of APOL1- Associated Nephropathy

Not Applicable

Withdrawn

Conditions: Kidney Disease

Interventions: Drug: Acthar

First Posted Date: 2013-12-10

Last Posted Date: 2017-11-07

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT02006849

Locations: 🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis

Early Phase 1

Completed

Conditions: Optic Neuritis

Interventions: Drug: ACTHAR

First Posted Date: 2013-11-19

Last Posted Date: 2017-08-22

Lead Sponsor: Neuro-Ophthalmologic Associates, PC

Target Recruit Count: 25

Registration Number: NCT01987167

Locations: 🇺🇸
Neuro Ophthalmology, Philadelphia, Pennsylvania, United States

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: ACTHAR

First Posted Date: 2013-11-14

Last Posted Date: 2021-01-15

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 15

Registration Number: NCT01984268

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Repository corticotropin injection

First Posted Date: 2013-10-22

Last Posted Date: 2016-08-18

Lead Sponsor: Arthritis Treatment Center, Maryland

Target Recruit Count: 8

Registration Number: NCT01966718

Locations: 🇺🇸
Arthritis Treatment Center, Frederick, Maryland, United States

ACTH in Progressive Forms of MS

Phase 2

Terminated

Conditions: Primary Progressive Multiple Sclerosis
Progressive Relapsing Multiple Sclerosis
Secondary Progressive Multiple Sclerosis

Interventions: Drug: Placebo
Drug: ACTH

First Posted Date: 2013-09-25

Last Posted Date: 2025-02-11

Lead Sponsor: University of Minnesota

Target Recruit Count: 59

Registration Number: NCT01950234

Locations: 🇺🇸
Sanford Clinic Neuroscience, Fargo, North Dakota, United States
🇺🇸
Clinical Neuroscience Research Unit, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Wheaton Franciscan Healthcare - St Francis Center for Neurological Disorders, Milwaukee, Wisconsin, United States

The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: corticotrophin 80 units

First Posted Date: 2013-09-23

Last Posted Date: 2019-01-18

Lead Sponsor: Gaylis, Norman B., M.D.

Target Recruit Count: 20

Registration Number: NCT01948388

Locations: 🇺🇸
AARDS Research, Inc, Aventura, Florida, United States

ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

Phase 4

Withdrawn

Conditions: SLE Glomerulonephritis Syndrome, WHO Class V

Interventions: Drug: Acthar gel

First Posted Date: 2013-08-20

Last Posted Date: 2018-05-11

Lead Sponsor: Ohio State University

Registration Number: NCT01926054

Locations: 🇺🇸
The Ohio State University Wexner Medical Center, Nephrology Clinical Trials Unit, Columbus, Ohio, United States

Comprehensive Analysis of Relapse in Multiple Sclerosis

Not Applicable

Conditions: Multiple Sclerosis

Interventions: Drug: Acthar Gel

First Posted Date: 2013-07-24

Last Posted Date: 2013-08-01

Lead Sponsor: Tanner Foundation for Multiple Sclerosis

Target Recruit Count: 20

Registration Number: NCT01906684

Locations: 🇺🇸
Tanner Center for MS, Birmingham, Alabama, United States

A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Repository corticotropin injection

First Posted Date: 2013-07-24

Last Posted Date: 2017-01-06

Lead Sponsor: Mallinckrodt

Target Recruit Count: 43

Registration Number: NCT01906658

Locations: 🇺🇸
Questcor Investigational Site, San Antonio, Texas, United States

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

Phase 2

Completed

Conditions: Dermatomyositis
Polymyositis

Interventions: Drug: Adrenocorticotropic Hormone Gel

First Posted Date: 2013-07-24

Last Posted Date: 2017-09-01

Lead Sponsor: Rohit Aggarwal, MD

Target Recruit Count: 12

Registration Number: NCT01906372

Locations: 🇺🇸
North Shore LIJ Medical Center, Great Neck, New York, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy